Aberrant promoter methylation of EDNRB in lung cancer in Taiwan

Oncology Reports

Volumn 15, Issue 1, 2006, Pages 167-172

  Chen, Shu Chen ^a,b   Lin, Chia Yu ^c   Chen, Ya Hui ^a,d   Fang, Hsin Yuan ^d   Cheng, Ching Yuan ^d   Chang, Chih Wen ^a   Chen, Ruei A ^d   Tai, Hui Lung ^a,d   Lee, Chien Hsing ^a,d   Chou, Ming Chih ^a   Lin, Torng Sen ^a,d   Hsu, Li Sung ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c ZHEJIANG UNIVERSITY   (China)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

EDNRB; Lung cancer; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DRUG DERIVATIVE; ENDOTHELIN B RECEPTOR;

ARTICLE; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; PATHOLOGY; PROMOTER REGION; TAIWAN;

AZACITIDINE; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; PROMOTER REGIONS (GENETICS); RECEPTOR, ENDOTHELIN B; SEQUENCE ANALYSIS, DNA; TAIWAN;

EID: 33644877611     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.1.167     Document Type: Article

References (30)

1. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
2. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE and Payne WS: Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 38: 331-338, 1984. (Pubitemid 14012545)
3. Zochbauer-Muller S, Minna JD and Gazdar AF: Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 7: 451-457, 2002. (Pubitemid 35266138)
4. Toyooka S, Toyooka KO, Maruyama R, et al: DNA methylation profiles of lung tumors. Mol Cancer Ther 1: 61-67, 2001.
5. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y and Motoyama T: Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 94: 589-592, 2003. (Pubitemid 36975012)
6. Toyooka KO, Toyooka S, Virmani AK, et al: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 61: 4556-4560, 2001. (Pubitemid 32685789)
7. Toyooka S, Toyooka KO, Miyajima K, et al: Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res 9: 3034-3041, 2003. (Pubitemid 36993264)
8. Usadel H, Brabender J, Danenberg KD, et al: Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum and plasma DNA of patients with lung cancer. Cancer Res 62: 371-375, 2002. (Pubitemid 34106406)
9. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF and Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancer. Cancer Res 61: 249-255, 2001. (Pubitemid 32095725)
10. Palmisano WA, Divine KK, Sacoomanno G, et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958, 2000.
11. Maruyama R, Sugio K, Yoshino I, Maehara Y and Gazdar AF: Hypermethylation of FHIT as a prognostic marker in non-small cell lung carcinoma. Cancer 100: 1472-1477, 2004. (Pubitemid 38366850)
12. Wang J, Lee JJ, Wang L, et al: Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 10: 6119-6125, 2004. (Pubitemid 39287517)
13. Puffenberger EG, Hosoda K, Washington SS, et al: A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 79: 1257-1266, 1994.
14. Duan XL, Zhang XS and Li GW: Clinical relationship between EDN-3 gene, EDNRB gene and Hirschsprung's disease. World J Gastroenterol 9: 2839-2842, 2003.
15. Eberle J, Weitmann S, Thieck O, Pech H, Paul M and Orfanos CE: Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. J Invest Dermatol 112: 925-932, 1999. (Pubitemid 29277994)
16. Pao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA and Jones PA: The endothelin receptor B promoter displays heterogenous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 10: 903-910, 2001. (Pubitemid 32401406)
17. Lo KW, Tsang YS, Kwong J, To KF, Teo PML and Huang DP: Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 98: 651-655, 2002. (Pubitemid 34225614)
18. Jeronimo C, Henrique R, Campos PF, et al: Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 56: 52-55, 2003. (Pubitemid 36132475)
19. Smith SL, Damato BE, Scholes AG, Nunn J, Field JK and Heighway J: Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. Br J Cancer 87: 1308-1313, 2002. (Pubitemid 36009138)
20. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
21. Jones PA and Laird PW: Cancer epigenetics come of age. Nat Genet 21: 163-167, 1999.
22. Fong KM, Sekido Y, Gazdar AF and Minna JD: Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax 58: 892-900, 2003. (Pubitemid 37239240)
23. Zochbauer-Muller S, Gazdar AF and Minna JD: Molecular pathogenesis of lung cancer. Annu Rev Physiol 64: 681-708, 2002. (Pubitemid 34259246)
24. Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717, 2004.
25. Kim DH, Nelson HH, Wiencke JK, et al: p16INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61: 3419-3424, 2001. (Pubitemid 32695035)
26. Belinsky SA, Nikula KJ, Baylin SB and Issa JP: Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc Natl Acad Sci USA 93: 4045-4050, 1996. (Pubitemid 26144243)
27. Lindsey JC, Lusher ME, Anderton JA, et al: Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 25: 661-668, 2004. (Pubitemid 38618517)
28. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64: 1975-1986, 2004. (Pubitemid 38339443)
29. Woodson K, Hanson J and Tangrea J: A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett 205: 181-188, 2004. (Pubitemid 38230125)
30. Nelson JB, Lww WH, Nguyen SH, et al: Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 57: 35-37, 1997. (Pubitemid 27020325)